Ascentage Pharma raises $15.5M in series A

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised $15.5 million in a series A round led by Oriza Seed Capital and YuanMing Capital. EFung Capital; BioVenture Capital; Grains Valley Venture Capital; and undisclosed investors also participated.

Ascentage's lead candidate is AT-101, a small molecule pan inhibitor of the Bcl-2 family of proteins. The candidate is in Phase II trials to treat chronic lymphocytic leukemia (CLL) and glioblastoma multiforme (GBM). ...